Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 9:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, tacrolimus
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
New York, New York • Cleveland, Ohio • Portland, Oregon + 2 more
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
24
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Conditions
Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, HIV Infection, Intraocular Lymphoma, Multicentric Angiofollicular Lymphoid Hyperplasia, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 2 more
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 2 more
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
CB-011
Biological
Lead sponsor
Caribou Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 12 more
Conditions
Multiple Myeloma
Interventions
Blenrep
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Timeline
2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
7 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Multiple Myeloma
Interventions
PRLX 93936
Drug
Lead sponsor
Prolexys Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Durham, North Carolina + 2 more
Conditions
Multiple Myeloma
Interventions
Interim/Maintenance Dexamethasone, Induction/Consolidation Dexamethasone, Induction/Consolidation Cisplatin, Induction/Consolidation Adriamycin, InductionConsolidation Cyclophosphamide, Induction/Consolidation Etoposide, Induction Pegfilgrastim, Transplant 1 Dexamethasone, Transplant 1 Cisplatin, Transplant 1 Adriamycin, Transplant 1 Cyclophosphamide, Transplant 1 Etoposide, Transplant 1 Melphalan, Transplant 1 and 2 Pegfilgrastim, Autologous Peripheral Blood Stem Cell Transplant (ASCT), Transplant 2 Carmustine, Transplant 2 Etoposide, Transplant 2 Cytarabine, Transplant 2 Melphalan, Transplant 2 Dexamethasone, Transplant 1 and 2 Bortezomib, Transplant 1 and 2 Thalidomide
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Multiple Myeloma
Interventions
carfilzomib, Dexamethasone, Clarithromycin, Lenalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Myeloma
Interventions
TempShield Continuous Temperature Monitoring, Standard of Care
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Conditions
Prostate Cancer
Interventions
Dovitinib, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma
Interventions
POM, Steroids, PLD, CFZ, BTZ, CLA, CY
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
Interventions
pomalidomide, marizomib, low-dose dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Conditions
Monoclonal Gammopathy of Undetermined Significance, Plasma Cell Myeloma
Interventions
5-Carbon C 13-labeled Glutamine, Biospecimen Collection, Uniformly-labeled [13C]glucose
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

AGA Biocellular Stem/Stromal Hair Regenerative Study

NCT02849470
Conditions
Hair Disease
Interventions
Intradermal Injection in hair loss, Platelet Rich Plasma, Adipose Derived Stem/Stromal Cells, Stem/Stromal Cellular Isolation (Digestive), MatriStem Matrix (ACell) - Current Standard of Care, HD-PRP (High Density Platelet Rich Plasma), Emulsified AD-tSVF, Emulsified AD-cSVF
Procedure
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Irvine, California
Conditions
Multiple Myeloma, Stem Cell Transplant Complications
Interventions
PARE, Waitlist Control Group
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Interventions
NX-5948
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Duarte, California • San Francisco, California • Denver, Colorado + 15 more
Conditions
Multiple Myeloma
Interventions
Eftozanermin alfa, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Boston, Massachusetts + 2 more
Conditions
Hemophilia A
Interventions
Recombinant Protein-Free Factor VIII (rAHF-PFM)
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Conditions
Myeloma
Interventions
Minocycline, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 1Phase 2 Interventional Results available

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

NCT02928029
Conditions
Multiple Myeloma
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Encinitas, California • Winston-Salem, North Carolina • Seattle, Washington